Meridian Bioscience, Inc., a life science company, develops, manufactures, and distributes diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; and enzyme-linked immunoassays under the Premier brand. This segment’s products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; Helicobacter pylori to detect peptic ulcers; respiratory products; and tests to detect Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, and outpatient clinics. The Life Science segment develops, manufactures, sells, and distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturing companies. It also provides contract development and manufacturing services under clinical cGMP conditions for biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.